Media ReleasesNoxopharm

View All Noxopharm News

Noxopharm Announces Evidence of Abscopal Responses in Patients

• Presentation at national oncology conference includes first 2 patients treated compassionately with NOX66 + radiotherapy

• Abscopal responses obtained in both patients

• Data supports Noxopharm approach for use of NOX66 in cancer treatment.

Sydney, 21 March 2018: Noxopharm (ASX:NOX) today presented a scientific update to the 30th Annual Scientific Meeting of the Trans Tasman Radiation Oncology Group (TROG), taking place in Hobart, Australia. As part of this update, two clinical cases – the first involving combination of NOX66 and radiotherapy – were presented. Both cases received NOX66 on a compassionate use outside of the Company’s formal clinical trial program.

For further information please download PDF attached:
Download this document